Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: The need for integration for optimal efficacy?

Julia K. Tietze, Gail D. Sckisel, Hui Hua Hsiao, William J Murphy

Research output: Contribution to journalArticle

5 Scopus citations


Due to its immunogenecity and evidence of immune responses resulting in tumor regression, metastatic melanoma has been the target for numerous immunotherapeutic approaches. Unfortunately, based on the clinical outcomes, even the successful induction of tumor-specific responses does not correlate with efficacy. Immunotherapies can be divided into antigen-specific approaches, which seek to induce T cells specific to one or several known tumor associated antigens (TAA), or with antigen-nonspecific approaches, which generally activate T cells to become nonspecifically lytic effectors. Here the authors critically review the different immunotherapeutic approaches in melanoma.

Original languageEnglish (US)
Pages (from-to)238-293
Number of pages56
JournalInternational Reviews of Immunology
Issue number5-6
StatePublished - Oct 2011



  • Adoptive transfer
  • Antibody
  • Antigen specific and nonspecific
  • Cytokine
  • Immunotherapy
  • Melanoma
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this